TEST:

GenomicsNext™ Liquid Biopsy

"GeneCentric Therapeutics...today announced the initial closing of an $8.0 million Series C financing. The proceeds will be used to launch and commercialize GeneCentric’s GenomicsNext™, the first integrated platform for comprehensive liquid biopsy testing that simultaneously provides thousands of gene expression measurements and high-fidelity DNA variant detection from circulating tumor DNA (ctDNA) in one sample. This novel gene expression platform will accelerate the growth of GeneCentric’s pipeline of predictive response signatures for oncology therapeutics development."